# Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

> **NCT05898984** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 69 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
- **DRUG:** Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI
- **DRUG:** Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

## Key facts

- **NCT ID:** NCT05898984
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-24
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-14
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898984, "Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05898984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*